{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:36:30Z","timestamp":1793097390181,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100389","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:23:38Z","timestamp":1786749818000},"page":"100389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The absorption, distribution, metabolism, excretion, and pharmacokinetic properties of the pan\u2013rapidly accelerated fibrosarcoma (RAF) inhibitor naporafenib in healthy subjects: An absolute bioavailability and mass balance study"],"prefix":"10.1016","volume":"54","author":[{"given":"Justine L.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongzhou","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfin","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Ling","family":"Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4051-884X","authenticated-orcid":false,"given":"Xiaoying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dmd.2026.100389_bib1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ccr.2011.04.002","article-title":"c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma","volume":"19","author":"Blasco","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.dmd.2026.100389_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110351","article-title":"CRAF dimerization with ARAF regulates KRAS-driven tumor growth","volume":"38","author":"Venkatanarayan","year":"2022","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.dmd.2026.100389_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12943-023-01903-x","article-title":"Targeting CRAF kinase in anti-cancer therapy: progress and opportunities","volume":"22","author":"Wang","year":"2023","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.dmd.2026.100389_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","article-title":"Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors","volume":"25","author":"Lito","year":"2014","journal-title":"Cancer Cell"},{"issue":"10539","key":"10.1016\/j.dmd.2026.100389_bib5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0140-6736(26)00199-6","article-title":"Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities","volume":"407","author":"Chan","year":"2026","journal-title":"Lancet"},{"issue":"7287","key":"10.1016\/j.dmd.2026.100389_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.dmd.2026.100389_bib7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF\u2014a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100389_bib8","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/1878-0261.13605","article-title":"Novel RAF-directed approaches to overcome current clinical limits and block the RAS\/RAF node","volume":"18","author":"Scardaci","year":"2024","journal-title":"Mol Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100389_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104634","article-title":"Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib","volume":"299","author":"Tkacik","year":"2023","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.dmd.2026.100389_bib10","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1021\/acs.molpharmaceut.4c00649","article-title":"Preclinical evaluation of a radiolabeled pan-RAF inhibitor for RAF-specific PET\/CT imaging","volume":"21","author":"Zhang","year":"2024","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.dmd.2026.100389_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/bjd\/ljaf178","article-title":"Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic","volume":"193","author":"Wang","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.dmd.2026.100389_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113458","article-title":"First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations","volume":"196","author":"Janku","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dmd.2026.100389_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107964","article-title":"A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer","volume":"197","author":"Planchard","year":"2024","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.dmd.2026.100389_bib14","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase Ib, open-label study","volume":"41","author":"de Braud","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100389_bib15","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/psp4.12466","article-title":"The importance of the human mass balance study in regulatory submissions","volume":"8","author":"Coppola","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100389_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jcph.569","article-title":"Approaches to intravenous clinical pharmacokinetics: recent developments with isotopic microtracers","volume":"56","author":"Lappin","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100389_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dmd.2026.100370","article-title":"Optimizing 14C-radiochemical doses for absorption, distribution, metabolism and elimination (ADME) studies: a predictive approach","volume":"54","author":"Vaz","year":"2026","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100389_bib19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100389_bib20","article-title":"Clinical pharmacology considerations for human radiolabeled mass balance studies","year":"2024","journal-title":"guidance for industry"},{"issue":"7","key":"10.1016\/j.dmd.2026.100389_bib21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:20:21Z","timestamp":1793096421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0090955626006586"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100389","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The absorption, distribution, metabolism, excretion, and pharmacokinetic properties of the pan\u2013rapidly accelerated fibrosarcoma (RAF) inhibitor naporafenib in healthy subjects: An absolute bioavailability and mass balance study","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100389"}}